Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ARX-788 |
| Synonyms | |
| Therapy Description |
ARX-788 is an antibody-drug conjugate (ADC) comprising a dolastatin analog and an antibody specific to ERBB2 (HER2), which may result in cell death and tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 639, PMID: 30841523, PMID: 32669315). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ARX-788 | ARX788|ARX 788 | HER2 (ERBB2) Antibody 79 HER2 (ERBB2) Antibody-Drug Conjugate 35 | ARX-788 is an antibody-drug conjugate (ADC) comprising a dolastatin analog and an antibody specific to ERBB2 (HER2), which may result in cell death and tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 639, PMID: 30841523, PMID: 32669315). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03255070 | Phase I | ARX-788 | A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) | Completed | USA | AUS | 0 |
| NCT05041972 | Phase II | ARX-788 | ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) | Withdrawn | USA | 0 |
| NCT04829604 | Phase II | ARX-788 | ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) | Active, not recruiting | USA | AUS | 1 |
| NCT06224673 | Phase II | ARX-788 | ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer | Not yet recruiting | USA | 0 |
| NCT01042379 | Phase II | GSK5733584 Zanidatamab Cemiplimab + VSV-hIFNbeta-NIS Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab ARX-788 Letrozole + Vepdegestrant Lasofoxifene Datopotamab deruxtecan + Durvalumab Abemaciclib + Vepdegestrant Dostarlimab-gxly + GSK5733584 Cemiplimab + Paclitaxel + Sarilumab Abemaciclib + Z-endoxifen HCl DAN-222 + Niraparib Datopotamab deruxtecan Vepdegestrant AZD2936 + Trastuzumab deruxtecan Z-endoxifen HCl | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY) | Recruiting | USA | 0 |
CKB BOOST